Research programme: cancer therapeutics - Boehringer Ingelheim/FORMA

Drug Profile

Research programme: cancer therapeutics - Boehringer Ingelheim/FORMA

Latest Information Update: 13 Jan 2014

Price : $50

At a glance

  • Originator Boehringer Ingelheim; FORMA Therapeutics
  • Class Small molecules
  • Mechanism of Action Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 09 Jan 2014 Early research is ongoing in USA
  • 05 Jan 2012 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top